S2 Changes in mitochondrial membrane potential (MMP) in PC-3 and LNCaP cells treated with LA-12/cisplatin and TRAIL. Percentage of PC-3 and LNCaP cells with decreased MMP (TMRE assay, flow cytometry) following pretreatment (24 h) with LA-12 (0.5/2.5 μM) or cisplatin (10/5 μM) and treatment (4 h) with TRAIL (5/20 ng/ml), respectively. Results are means ± S.E.M. of 3 independent experiments. Statistical significance (P < 0.05, * vs. control, † vs. TRAIL, □ vs. appropriate platinum drug).